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Abstract
Background: Type 2 diabetes (T2D) is a disease effecting people of every age, ethnicity, and gender and rates
of the disease do not appear to be declining in the near future. The road to T2D is characterized by the
combination of peripheral insulin resistance and inadequate insulin secretion by pancreatic beta cells.
Although the factors that contribute to the development of T2D are complex and not fully elucidated, the
triad of severe obesity, hyperinsulinemia, and a family history of T2D is known to place a child at an increased
risk for subsequent development of the disease. The purpose of this study is to explore the preventative
potential of metformin in obese, non-diabetic adolescents at-risk for the development of T2D.
Methods: An exhaustive search of available medical literature was conducted using Medline-OVID,
CINAHL, and Google Scholar using the key words: adolescents, metformin, diabetes – prevention and
control, obesity, and diabetic risk factors. Articles with primary data evaluating the use of metformin in obese,
non-diabetic adolescents were included. These relevant articles were assessed for quality using the Grading of
Recommendations, Assessment, Development and Evaluation (GRADE).
Results: Three studies met the inclusion criteria for this systematic review of literature. A double-blind,
placebo-controlled study of the effects of metformin on body mass index and glucose tolerance in 29 obese
adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes demonstrated a significant
decline in BMI and decreased insulin and glucose concentrations. Another double-blind, placebo-controlled
study of metformin in non-diabetic, hyperinsulinemic, obese adolescents maintained on a low-calorie diet
demonstrated statistically significant weight loss in the metformin group as well as improved insulin
concentrations. Lastly, a randomized double-blind placebo-controlled trial evaluating metformin in addition
to personal goal setting with weight loss and clinical status in 85 obese adolescents with insulin resistance
demonstrated significant decrease in BMI in females with metformin adherence and lifestyle changes.
Conclusion: Metformin has been demonstrated to aid with weight loss and insulin sensitivity in select obese,
non-diabetic adolescents with risk factors for diabetes. The overall combined quality of the studies reviewed is
low based on the GRADE criteria. A recommendation for the use of metformin in obese, non-diabetic, at-risk
adolescents who are motivated to create lifestyle changes can be given at this time for short term weight loss
goals and increasing insulin sensitivity.
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Abstract   
 
Background:  Type 2 diabetes (T2D) is a disease effecting people of every age, 
ethnicity, and gender and rates of the disease do not appear to be declining in the near 
future. The road to T2D is characterized by the combination of peripheral insulin 
resistance and inadequate insulin secretion by pancreatic beta cells. Although the factors 
that contribute to the development of T2D are complex and not fully elucidated, the triad 
of severe obesity, hyperinsulinemia, and a family history of T2D is known to place a 
child at an increased risk for subsequent development of the disease. The purpose of this 
study is to explore the preventative potential of metformin in obese, non-diabetic 
adolescents at-risk for the development of T2D. 
 
Methods:  An exhaustive search of available medical literature was conducted using 
Medline-OVID, CINAHL, and Google Scholar using the key words: adolescents, 
metformin, diabetes – prevention and control, obesity, and diabetic risk factors. Articles 
with primary data evaluating the use of metformin in obese, non-diabetic adolescents 
were included. These relevant articles were assessed for quality using the Grading of 
Recommendations, Assessment, Development and Evaluation (GRADE). 
 
Results:  Three studies met the inclusion criteria for this systematic review of literature. 
A double-blind, placebo-controlled study of the effects of metformin on body mass index 
and glucose tolerance in 29 obese adolescents with fasting hyperinsulinemia and a family 
history of type 2 diabetes demonstrated a significant decline in BMI and decreased 
insulin and glucose concentrations. Another double-blind, placebo-controlled study of 
metformin in non-diabetic, hyperinsulinemic, obese adolescents maintained on a low-
calorie diet demonstrated statistically significant weight loss in the metformin group as 
well as improved insulin concentrations. Lastly, a randomized double-blind placebo-
controlled trial evaluating metformin in addition to personal goal setting with weight loss 
and clinical status in 85 obese adolescents with insulin resistance demonstrated 
significant decrease in BMI in females with metformin adherence and lifestyle changes. 
 
Conclusion:  Metformin has been demonstrated to aid with weight loss and insulin 
sensitivity in select obese, non-diabetic adolescents with risk factors for diabetes. The 
overall combined quality of the studies reviewed is low based on the GRADE criteria. A 
recommendation for the use of metformin in obese, non-diabetic, at-risk adolescents who 
are motivated to create lifestyle changes can be given at this time for short term weight 
loss goals and increasing insulin sensitivity. 
 
Keywords: adolescents, metformin, diabetes, obesity, and diabetic risk factors. 
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Clinical Use of Metformin in Non-Diabetic, Obese, At-Risk Adolescents: A 
Systematic Review 
BACKGROUND 
 Type 2 diabetes (T2D) is a disease effecting people of every age, ethnicity, and 
gender and rates of the disease do not appear to be declining in the near future. Rates of 
diabetes are increasing worldwide. The International Diabetes Federation predicts that the 
number of people living with diabetes will rise from 366 million in 2011 to 552 million 
by 2030.
1
 The culprit of these spiking numbers is largely due to the increased intake of 
carbohydrate rich foods and sedentary lifestyles leading to obesity. Most commonly, T2D 
occurs in adults over the age of 40 and rates increase with age. The Center for Disease 
Control and Prevention (CDC) reports that in 2005-2008, based on fasting glucose or 
hemoglobin A1c levels, 35% of U.S. adults aged 20 years or older had prediabetes (50% 
of adults aged 65 years or older). Applying this percentage to the entire U.S. population 
in 2010 yields an estimated 79 million American adults aged 20 years or older with 
prediabetes. The CDC also states about 215 000 people younger than 20 years had 
diabetes (type 1 or type 2) in the United States in 2010.
2
 Most of them have type 1 
diabetes, but as obesity rates in children continue to soar, T2D is becoming more of a 
reality in young people. Genetics play a large role as well, 30% of patients have a 
positive family history of T2D. Also, increased prevalence of T2D is found in patients 
with the following risk factors: excessive weight (85% of patients), poor physical fitness, 
and genetic predisposition.
3
  
The road to T2D is characterized by the combination of peripheral insulin 
resistance and inadequate insulin secretion by pancreatic beta cells. For type 2 diabetes 
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mellitus to occur, both insulin resistance and inadequate insulin secretion must exist. For 
example, all overweight individuals have insulin resistance, but diabetes develops only in 
those who cannot increase insulin secretion sufficiently to compensate for their insulin 
resistance. Their insulin concentrations may be high, yet inappropriately low for the level 
of glycemia. In the progression from normal to abnormal glucose tolerance, postprandial 
blood glucose levels increase first. Eventually, fasting hyperglycemia develops as 
suppression of hepatic gluconeogenesis fails.
4
 Although the factors that contribute to the 
development of T2D are complex and not fully elucidated, the triad of severe obesity, 
hyperinsulinemia, and a family history of T2D is known to place a child at an increased 
risk for subsequent development of the disease.
5
  
The prevention of T2D in at-risk adults currently consists mainly of diet and 
exercise modifications and in some cases the use of metformin. The exact mechanism of 
action of metformin is unknown, but it has been shown to decrease hepatic glucose 
production, decrease intestinal absorption of glucose, and improve insulin sensitivity in 
peripheral tissues. Recently, the Diabetes Prevention Program Outcomes study concluded 
that in adults, metformin used for diabetes prevention is safe and well tolerated. Weight 
loss is related to adherence to metformin and is durable for at least 10 years of treatment.
6 
The purpose of this study is to explore the preventative potential of metformin in 
obese, non-diabetic adolescents at-risk for the development of T2D. This review will 
primarily be looking at outcomes associated with weight loss and decreasing insulin 
levels and sensitivity.  
METHODS 
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 An exhaustive search of available medical literature was conducted using 
Medline-OVID, CINAHL, and Google Scholar using the key words: adolescents, 
metformin, diabetes – prevention and control, obesity, and diabetes risk factors. Articles 
with primary data evaluating the use of metformin in obese non-diabetic adolescents were 
included. These relevant articles were assessed for quality using the Grading of 
Recommendations, Assessment, Development and Evaluation (GRADE).
7 
RESULTS 
 The initial search produced 128 articles for review. After screening of these 
articles, 3 of these met the inclusion criteria. Each of the 3 were randomized-controlled 
trials.
5,8,9
 
Freemark and Bursey Study (2001) 
 This randomized, double blind, placebo-controlled trial
5
 studied the effects of 
metformin on body mass index (BMI), serum leptin, glucose tolerance, and serum lipids 
in obese adolescents with fasting hyperinsulinemia and family history of type 2 diabetes. 
Because the investigation was designed to assess the effects of metformin on glucose 
tolerance and weight gain in the absence of dietary intervention, the researchers made no 
attempt to control the caloric intake or food selection of the patients.
5 
A total of 32 patients were enrolled in the study in a randomized, double-blinded 
manner. All were between 12 and 19 years old and had a BMI exceeding 30 kg/m
2
. 
Criteria for enrollment included: 1) a fasting insulin concentration exceeding 15µU/mL 
and 2) at least 1, first- or second-degree relative (parent, sibling, or grandparent) with 
T2D. All patients had normal fasting glucose concentrations (<110 mg%) and HbA1c 
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concentrations (≤6.0%), and none had glycosuria or ketonuria. The final analysis 
included data from 14 metformin-treated participants and 15 placebo controls.
5 
 After completing intravenous lab testing and intravenous glucose tolerance test, 
the patient was discharged with either metformin (500mg) or placebo. Patients were 
instructed to take one pill at breakfast and one at supper each day. Compliance with the 
medication was assessed by patient reports and by pill counts at each monthly visit.  
Because BMI in the normal population varies according to age, gender, and ethnic 
background, they expressed absolute values of BMI as standard deviation scores (SDS) 
and changes in BMI as changes in SDS. Changes in insulin sensitivity were assessed by 
quantifying changes in: 1) the ratio of fasting insulin to glucose concentrations, 2) the 
quantitative insulin sensitivity check index (QUICKI; 1/[log fasting insulin + log fasting 
glucose]), and 3) the homeostasis model assessment insulin resistance index (HOMA-IR; 
fasting insulin × fasting glucose/22.5). QUICKI and HOMA-IR are calculated from the 
fasting concentrations of glucose and insulin. A P value <.05 was considered statistically 
significant.
5 
 At baseline, BMI of patients in the metformin treatment group was 7.2% (P < .05) 
greater than that of patients in the placebo group. There was no statistical difference 
between groups in baseline plasma glucose or insulin, calculated insulin sensitivity or 
glucose effectiveness, or HbA1c.
5 
The authors found that metformin caused a decline of 0.12 SD in BMI during the 
study, amounting to a mean decrease of 0.5 kg/m
2
, or -1.3% from baseline. In contrast, 
BMI rose 0.23 SD, or 2.3% (mean + 0.9 kg/m
2
) in the placebo group. The differences in 
absolute and percent change in BMI SDS in the 2 groups were statistically significant (P 
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< .02). Metformin caused a progressive decline in fasting blood glucose levels, from 84 ± 
2.2 mg% at the start of the study to 75 ± 1.6 mg% at the end of the 6-month trial (P < 
.02). In contrast, fasting blood glucose levels in the placebo group did not change 
significantly during the study. Fasting insulin concentrations in the metformin group 
declined from 31.5 ± 3.3 µU/mL at baseline to 19.2 ± 1.5 µU/mL after 6 months of 
treatment (P < .01). In contrast, insulin levels did not change in the placebo group. Lastly, 
metformin caused a significant (P < .01) albeit small increase in insulin sensitivity as 
assessed by: 1) the ratio of fasting insulin to glucose concentration, 2) QUICKI, and 3) 
HOMA-IR.
5 
 Two placebo patients and a metformin-treated patient failed to complete the study 
for reasons unrelated to drug toxicity or to complications of the trial and were not 
included in the final analysis.
5 
 The authors found a limitation to this study was due to the small number of 
patients, therefore, the results must be confirmed in a larger sample.  Also, treatment and 
control groups were not matched precisely for ethnic background, gender, or initial BMI. 
They discussed the consequences of these differences may have been negated in part 
because: 1) they expressed the absolute values for BMI as SDS, thereby correcting in part 
for differences in ethnic background, age, and gender and 2) they expressed changes in 
BMI in their patients as changes in SDS, and changes in plasma glucose, insulin, leptin, 
and lipids as a percentage of each individual’s baseline value allowing to use each patient 
as his or her own control during the study.  Next, the study lasted only 6 months and it 
was discussed whether the positive effects of metformin and drug safety would be 
sustained over longer periods.  Lastly, effects of metformin on BMI and fasting blood 
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glucose and insulin levels, although statistically significant, were relatively small in 
magnitude.
5 
The authors concluded that metformin therapy might complement the effects of 
dietary and exercise counseling and reduce the risk of type 2 diabetes and can be 
considered in selected obese adolescent patients with a family history of the disease.
5 
Kay et al Study (2001) 
 This 8-week randomized, double-blind, placebo-controlled trial
8
 evaluated the 
anti-obesity effect of metformin in hyperinsulinemic, non-diabetic, obese adolescents. 
Subjects consisted of 24 Caucasian obese adolescents with a BMI greater than 30 kg/m
2
. 
Subjects with a history of glucose intolerance, diabetes, renal disorders, previously 
identified endocrine disorders, and cardiovascular disease were excluded, as well as those 
with a fasting glucose greater than 120 mg/dL and/or and HgbA1c ≥ 7.0%. There were no 
significant differences in age, weight, BMI, or reported caloric intake between the two 
groups.
8 
 Before beginning the study, all participants were placed on a hypocaloric diet and 
the placebo medication for a 1-week. This was used as a lead-in period to exclude 
individuals unlikely to be compliant and ensure a stable body weight before 
randomization.  Subjects were randomly assigned to two, double-blind treatment groups: 
12 received metformin for 8 weeks and 12 received a placebo.  All subjects were initially 
started on metformin (850 mg) or placebo once daily.  After 1 week, metformin or 
placebo was increased to twice daily for the remainder of the study.  The compliance 
rates for both groups were comparable.  Each subject underwent a comprehensive 
nutritional evaluation by a registered dietitian and was instructed to complete 24-hour 
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food records for each of the nine weeks of the study. Before commencing, and after 
completion of the study, the following laboratory tests were obtained: fasting plasma 
glucose, insulin, leptin, cholesterol, triglycerides, and free fatty acids (FFA). Glucose-
stimulated insulin response and insulin sensitivity were determined both before and after 
completing the study by an oral glucose tolerance test (OGTT).
8 
 After 8 weeks, some weight loss was observed in both placebo and metformin 
groups.  However, the weight loss was greater in the metformin group (-6.1 ± 0.8 kg) 
than in the placebo group (-3.2 ± 2.0 kg, P < .01).  There were no significant differences 
in glucose, insulin, leptin, and lipids between the 2 groups at the beginning of the study.  
After treatment, the decrease in fasting insulin (P < .025) was greater in the metformin 
group than in the placebo group, without a significant change in fasting glucose. 
Metformin treatment resulted in a marked decrease in the areas under the curve (AUCs) 
for insulin as compared with control subjects (P < .001), without a significant change in 
AUCs for glucose in either group.  However, this was associated with a significant 
increase in the AUC glucose: AUC insulin ratio and the 2-hour glucose: insulin ratio (P < 
.01) following metformin treatment without a significant change in the placebo group. 
Metformin administration caused minimal side effects in five of 12 subjects which 
resolved.
8 
 The authors admit the limitations of having a small sample size and short duration 
of the study that larger and long-term studies may be needed to evaluate the metabolic 
and anti-obesity effects of metformin in hyperinsulinemic, obese adolescents.
7 
The authors conclude that the present study demonstrated that metformin 
treatment leads to significant weight loss and decrease in body fat in hyperinsulinemic 
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obese adolescents.  Also this study portrays a significant increase in insulin sensitivity in 
metformin-treated subjects without a significant change in glycemia and lipid profile in 
the metformin group.  The anti-obesity effect of metformin may be therapeutically 
beneficial in the management of obese hyperinsulinemic patients.
8 
Love-Osborne el al Study (2008) 
 In this 6 month randomized, double-blind, placebo-controlled trial
9
, the authors 
sought to evaluate whether metformin, when added to a program of personal goal setting, 
improves weight loss and clinical status in obese adolescents.
9 
The study consisted of 85 adolescents aged 12-19 years that were invited to a 
screening visit where a family history, physical exam, and fasting laboratory evaluations 
were obtained.  Participants who had fasting insulin level > 25 microunits/mL or HOMA 
(Homeostasis mode assessment: fasting insulin in microunits/mL × fasting glucose in 
millimoles/liter/22.5) > 3.5 and 2 out of 3 risk factors (presence of acanthosis nigiricans, 
obesity (BMI > 95% for age), or family history of type 2 diabetes) were invited to 
participate in the study.  At the first visit, baseline labs were drawn, history was taken, 
and subjects underwent a 2-hour oral glucose tolerance test. Subjects worked with a 
dietitian or study investigator to choose 3 goals for themselves, related to dietary or 
exercise changes and were instructed to record progress on their goals and whether or not 
they took the medication on a calendar.
9 
 Subjects were randomized 2:1 to receive metformin or placebo.  Randomization 
was stratified by race (AA or other) and fasting insulin level (greater than or less than 40 
IU/mL).  Subjects were started on metformin (500 mg) or placebo once daily. At one 
month, the dose increased to 500 mg twice daily, followed by an increase to 850 mg 
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twice daily at 2 months.  Subjects were seen monthly for measurement of weight and BP, 
urine pregnancy test if indicated, assessment of adherence to goals, contraception, alcohol 
consumption, and adherence with the tolerability of treatment.
9 
 The authors reported that 85 subjects were enrolled. The mean age was 15.7 years 
and mean BMI 39.7 kg/m
2
.  Seventy-one percent of the subjects were female.  Eighty 
percent of metformin subjects and sixty-four percent of placebo subjects completed the 6-
month visit.  Fifty percent of metformin and forty-eight percent of placebo subjects 
completed at least five of seven possible visits.
9 
 Goal setting alone did not lead to weight loss in this group of adolescents. 
Subjects adherent with metformin (N= 30) decreased BMI to the greatest extent, though 
subjects with lower adherence to metformin gained less weight than adherent subjects on 
placebo (0.1 kg/m
2
 vs. 0.63 kg/m
2
).  Of subjects on metformin with good medication 
adherence, 8 (27%) attained BMI decrease of 5%.  Among those who took all 6 bottles of 
metformin (N = 14), 5 (36%) decreased BMI by 5%.  Females were twice as likely as 
males to decrease their BMI by 5% or more (p = .002). Subjects who reported a decrease 
in portion size, and were also adherent with metformin (N = 10) lost significantly more 
weight (BMI -1.3 kg/m
2
, p = .005) than adherent subjects not reporting decreased portion 
size, non adherent subjects irrespective of change in portion size and all placebo groups 
(BMI +.4 kg/m
2
 for all other groups).  Strikingly, 60% of metformin adherent subjects 
who reported decreased portion size were able to decrease BMI by 5% (p = .02). There 
were no statistical differences in the change of laboratory values at 6 months between 
subjects receiving metformin and placebo. However, a decrease in BMI of 5% or greater 
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was associated with a mean improvement in 2-hour glucose concentration of 11.6 mg/dL 
(p = .03).
9 
 The author reported limitations to this study include subjects that dropped out of 
the study after the first off-site visit had almost universally gained weight, on metformin 
or placebo. It was discussed that the rate of dropouts may suggest that many adolescents 
will not continue with a program that does not show rapid results.  Also the relatively 
small number of subjects may have influenced the lack of observed benefit in laboratory 
values.  Finally, this study examined the use of metformin for a period of only 6 months.  
Discussion that the efficacy of many weight loss interventions wanes with time, therefore 
future research should address beneficial effects of metformin persist over a longer period 
of time.
9 
 The authors conclude, the results indicate that metformin was beneficial as a 
weight loss medication in a subset of obese adolescents with insulin resistance.  Girls 
taking metformin had a significant decrease in BMI compared with those taking placebo 
and were much less likely to gain weight than boys.  Increasing metformin adherence was 
associated with a higher likelihood of significant BMI decrease as well.
9 
DISCUSSION 
 After review of these studies, metformin in the short term can moderately aid in 
weight loss and insulin sensitivity in obese at-risk adolescents.
5,8,9
 The outcomes 
observed and discussed by these three articles suggest weight loss and decreasing insulin 
levels and resistance to insulin will in turn aid to prevent the eventual progression to type 
2 diabetes in select patients.  Therefore, the discussion and outcome of most importance 
is weight loss followed by changes in insulin levels and insulin sensitivity.  
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Weight Loss 
 Weight loss or decrease in BMI was observed in all studies that were reviewed.  
First, Freemark and Bursey
5
 observed a mean decrease of 0.5 kg/m
2
 in the metformin 
treatment group while BMI rose by a mean of 0.9 kg/m
2
 in the placebo group which was 
statistically significant. 
 
This study was purposely conducted in the absence of dietary 
intervention. Second, Kay et al
8
 evaluated subject’s weight loss on metformin vs placebo 
in the presence of a low-calorie meal plan (1500 kcal for women and 1800 kcal for men). 
They observed a statistically significant weight loss greater in the metformin group (-6.1 
± 0.8 kg) than in the placebo group (-3.2 ± 2.0 kg). Finally, Love-Osborne et al
9
 
evaluated weight loss in subjects along with monthly goal setting for diet and exercise 
modification. Goal setting alone did not result in significant weight loss.  They also found 
there was no overall difference in weight loss between subjects receiving metformin or 
placebo.  However, 11 subjects on metformin and no subjects on placebo had a BMI 
decrease of 5% or more.  Females on metformin had a mean BMI decrease of the greatest 
extent. 
Insulin Levels/Sensitivity 
 After reviewing these articles, only 2 out of 3 measured pre and post insulin levels 
and/or evaluated insulin sensitivity in some fashion.  Love-Osborne et al
9
 only performed 
a pre and post oral glucose tolerance test (OGTT) that will be discussed.  First, Freemark 
and Bursey
5
 observed statistically significant fasting insulin concentrations in the 
metformin group declined from 31.5 ± 3.3 µU/mL at baseline to 19.2 ± 1.5 µU/mL after 
6 months of treatment.  In contrast, fasting insulin levels did not change in the placebo 
group.  Metformin also caused a significant albeit small increase in insulin sensitivity as 
 - 17 - Revised 07Dec2009 
assessed by: 1) the ratio of fasting insulin to glucose concentration, 2) QUICKI, and 3) 
HOMA-IR. Second, Kay et al
8
 displayed a significant decrease in fasting insulin levels in 
the metformin group (-21 ± 6 µU/mL) in comparison to placebo (-11 ± 5 µU/mL) without 
a significant change in fasting glucose.  Also noted, the areas under the curve (AUCs) as 
measured by the response to OGTT for insulin decreased with metformin as compared 
with control subjects (p = .001). Finally, Love-Osborne et al
9
 did not directly observe 
serum insulin levels, although the authors did perform a pre and post OGTT that revealed 
a link between weight loss and glucose tolerance.  They found a decrease in BMI of 5% 
or greater was associated with a mean improvement in 2-hour glucose concentration of 
11.6 mg/dL (p = .03).  Subjects with baseline IFG (Impaired Fasting Glucose), IGT 
(Impaired Glucose Tolerance) or IFG/IGT were more likely to improve if they lost 
weight.
 
Quality Assessment 
 All three studies evaluated the outcome of weight loss while only 2 of the 3 
looked at the sensitivity of insulin.  Following GRADE protocol, all 3 studies being 
RCTs began with a GRADE of high.  Both outcomes, weight loss and insulin sensitivity, 
were downgraded two levels for lack of precision. These studies admit to being of small 
sample size and short duration in nature. Overall, the GRADE rating of low was given to 
both outcomes of weight loss and insulin sensitivity. See Table 1. 
CONCLUSION 
Metformin has been demonstrated to aid with weight loss and insulin sensitivity 
in select obese, non-diabetic adolescents with risk factors for diabetes.  The results from 
the studies reviewed emphasize specifically that in combination with either dietary 
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restriction or setting goals for lifestyle modification, the use of metformin in these 
adolescents will decrease BMI and serum insulin levels. Also, the only study looking at 
sex differences pointed out a significant decrease in BMI in females compared to males 
using metformin. As recommended by the authors of these studies, to evaluate the 
sustained benefits of metformin there is a need for more long term research with larger 
sample sizes. The overall combined quality of the studies reviewed is low based on the 
GRADE criteria. A recommendation for the use of metformin in obese, non-diabetic, at-
risk adolescents who are motivated to create lifestyle changes can be given at this time 
for short term weight loss goals and increasing insulin sensitivity.  Further randomized 
controlled studies evaluating the sustained effects of metformin on the outcomes 
addressed as well as clinical status, sex differences, and ethnically diverse adolescents 
will be of great importance. 
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Table I. Characteristics of Reviewed Studies 
(GRADE TABLE) 
 
 
 
 
 
 
 
 
 
 
aSmall sample size and short duration within each RCT reviewed. 
Quality Assessment  
Importance  Downgrade Criteria 
Quality 
No. of 
Studies 
Design Limitations Indirectness Imprecision Inconsistency 
Publication 
bias likely 
Weight Loss   
 
 
3 
 
 
3 RCT 
No serious 
limitations 
No serious 
indirectness 
Very serious 
imprecisiona 
No serious 
inconsistencies 
No bias 
likely 
Low Important 
Insulin Sensitivity    
2 2 RCT 
No serious 
limitations 
No serious 
indirectness 
Very serious 
imprecisiona 
No serious 
inconsistencies 
No bias 
likely 
Low Important 
